SHZ:300122

Chongqing Zhifei Biological Products Co., Ltd. · SHZ · Healthcare · CNY · FY for 2025

Figures on this page computed 2026-11-08 00:17 UTC

Last close

n/aCNY

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
-57.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-164.3%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
50.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.78Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
1.0%Dividend yield
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed

Growth is the furthest below its sector's middle: 0.05 against 0.50 on the market's range.

Five bars, one line

lens 7 of 9

0.47x

-7.11x

2.60x

3.36x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.47x
Its own average over 10 years, 18.97B.
Profit-7.11x
Its own average over 10 years, 2.07B.
Free cash flow2.60x
Its own average over 10 years, 1.75B.
Debt3.36x
Its own average over 10 years, 3.65B.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at -7.11 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Profit	Shares in issue
2016-12-31	100.0	100.0	100.0
2017-12-31	301.1	1,329.2	103.0
2018-12-31	1,172.4	4,463.0	103.0
2019-12-31	2,374.1	7,276.8	103.0
2020-12-31	3,406.3	10,151.6	103.0
2021-12-31	6,873.6	31,391.3	103.0
2022-12-31	8,580.4	23,182.4	154.5
2023-12-31	11,866.4	24,814.9	154.5
2024-12-31	5,845.9	6,206.8	154.2
2025-12-31	2,008.9	-45,273.7	154.1

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How profit was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

Figures behind the shape

Growth

-10.0%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-10.0%
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
One-year change in net income-829.4%
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed

Returns on capital

-57.7%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital-57.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity-93.0%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets-46.4%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

-144.2%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin-144.2%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin-194.9%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin-164.3%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin50.8%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

2.3x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
Price to book2.3x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio4.0x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

0.78

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.78
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio1.53
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score0.63
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

1.0%

more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07

Dividend yield1.0%
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio13.2x
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.